Cargando…
A recent development of new therapeutic agents and novel drug targets for cancer treatment
Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725032/ https://www.ncbi.nlm.nih.gov/pubmed/34992782 http://dx.doi.org/10.1177/20503121211067083 |
_version_ | 1784626032819568640 |
---|---|
author | Kifle, Zemene Demelash Tadele, Meklit Alemu, Eyerusalem Gedamu, Tadele Ayele, Akeberegn Gorems |
author_facet | Kifle, Zemene Demelash Tadele, Meklit Alemu, Eyerusalem Gedamu, Tadele Ayele, Akeberegn Gorems |
author_sort | Kifle, Zemene Demelash |
collection | PubMed |
description | Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its stage. Thus, this review aimed to summarize a recent development of new therapeutic agents and novel drug targets for the treatment of cancer. Several obstacles stand in the way of effective cancer treatment and drug development, including inaccessibility of tumor site by appropriate drug concentration, debilitating untoward effects caused by non-selective tissue distribution of chemotherapeutic agents, and occurrence of drug resistance, which leads to cross-resistance to a variety of drugs. Resistance to treatment with anticancer drugs results from multiple factors and the most common reason for acquiring drug resistance is marking and expelling drugs that prevent cancer cells to be targeted by chemotherapeutic agents. Moreover, insensitivity to drug-induced apoptosis, alteration, and mutation of drug target and interference/change of DNA replication are other main causes of treatment failure. |
format | Online Article Text |
id | pubmed-8725032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87250322022-01-05 A recent development of new therapeutic agents and novel drug targets for cancer treatment Kifle, Zemene Demelash Tadele, Meklit Alemu, Eyerusalem Gedamu, Tadele Ayele, Akeberegn Gorems SAGE Open Med Review Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its stage. Thus, this review aimed to summarize a recent development of new therapeutic agents and novel drug targets for the treatment of cancer. Several obstacles stand in the way of effective cancer treatment and drug development, including inaccessibility of tumor site by appropriate drug concentration, debilitating untoward effects caused by non-selective tissue distribution of chemotherapeutic agents, and occurrence of drug resistance, which leads to cross-resistance to a variety of drugs. Resistance to treatment with anticancer drugs results from multiple factors and the most common reason for acquiring drug resistance is marking and expelling drugs that prevent cancer cells to be targeted by chemotherapeutic agents. Moreover, insensitivity to drug-induced apoptosis, alteration, and mutation of drug target and interference/change of DNA replication are other main causes of treatment failure. SAGE Publications 2021-12-23 /pmc/articles/PMC8725032/ /pubmed/34992782 http://dx.doi.org/10.1177/20503121211067083 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Kifle, Zemene Demelash Tadele, Meklit Alemu, Eyerusalem Gedamu, Tadele Ayele, Akeberegn Gorems A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title | A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title_full | A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title_fullStr | A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title_full_unstemmed | A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title_short | A recent development of new therapeutic agents and novel drug targets for cancer treatment |
title_sort | recent development of new therapeutic agents and novel drug targets for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725032/ https://www.ncbi.nlm.nih.gov/pubmed/34992782 http://dx.doi.org/10.1177/20503121211067083 |
work_keys_str_mv | AT kiflezemenedemelash arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT tadelemeklit arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT alemueyerusalem arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT gedamutadele arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT ayeleakeberegngorems arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT kiflezemenedemelash recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT tadelemeklit recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT alemueyerusalem recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT gedamutadele recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment AT ayeleakeberegngorems recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment |